PL3603620T3 - Kompozycja liposomowa i kompozycja farmaceutyczna - Google Patents
Kompozycja liposomowa i kompozycja farmaceutycznaInfo
- Publication number
- PL3603620T3 PL3603620T3 PL18776957.5T PL18776957T PL3603620T3 PL 3603620 T3 PL3603620 T3 PL 3603620T3 PL 18776957 T PL18776957 T PL 18776957T PL 3603620 T3 PL3603620 T3 PL 3603620T3
- Authority
- PL
- Poland
- Prior art keywords
- composition
- liposome
- pharmaceutical composition
- pharmaceutical
- liposome composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/02—Ammonia; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017069836 | 2017-03-31 | ||
| PCT/JP2018/013783 WO2018181963A1 (ja) | 2017-03-31 | 2018-03-30 | リポソーム組成物および医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3603620T3 true PL3603620T3 (pl) | 2026-02-16 |
Family
ID=63676279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18776957.5T PL3603620T3 (pl) | 2017-03-31 | 2018-03-30 | Kompozycja liposomowa i kompozycja farmaceutyczna |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US11413244B2 (pl) |
| EP (1) | EP3603620B1 (pl) |
| JP (3) | JP6728482B2 (pl) |
| KR (1) | KR102328463B1 (pl) |
| CN (4) | CN114224840A (pl) |
| AU (1) | AU2018246024B2 (pl) |
| BR (1) | BR112019020406B1 (pl) |
| CA (1) | CA3058127C (pl) |
| DK (1) | DK3603620T3 (pl) |
| ES (1) | ES3055110T3 (pl) |
| FI (1) | FI3603620T3 (pl) |
| HR (1) | HRP20251519T1 (pl) |
| LT (1) | LT3603620T (pl) |
| PL (1) | PL3603620T3 (pl) |
| PT (1) | PT3603620T (pl) |
| RS (1) | RS67470B1 (pl) |
| RU (1) | RU2734900C1 (pl) |
| SI (1) | SI3603620T1 (pl) |
| SM (1) | SMT202500440T1 (pl) |
| WO (1) | WO2018181963A1 (pl) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202500440T1 (it) * | 2017-03-31 | 2026-01-12 | Fujifilm Corp | Composizione liposomiale e composizione farmaceutica |
| WO2019244979A1 (ja) * | 2018-06-20 | 2019-12-26 | 富士フイルム株式会社 | 薬物を内包するリポソーム組成物および免疫チェックポイント阻害剤を含む組合せ医薬 |
| TWI837189B (zh) * | 2018-10-01 | 2024-04-01 | 日商富士軟片股份有限公司 | 包含內含藥物之脂質體組成物及鉑製劑之組合醫藥 |
| CA3116146A1 (en) | 2018-12-17 | 2020-06-25 | Eisai R&D Management Co., Ltd. | Formulation comprising liposomes |
| CN115605196A (zh) * | 2020-05-06 | 2023-01-13 | 纳米科技制药公司（Us） | 用于治疗癌症和癌症耐药性的脂质体制剂 |
| CN113876711A (zh) * | 2020-07-01 | 2022-01-04 | 江苏长泰药业有限公司 | 一种盐酸阿霉素脂质体的制备工艺 |
| CN116635009A (zh) * | 2020-12-14 | 2023-08-22 | 纳米科技制药公司 | 用于递送抗癌剂的具有改进的治疗指数的组合物和方法 |
| JP6884496B1 (ja) * | 2021-03-08 | 2021-06-09 | ユーシービージャパン株式会社 | レベチラセタムを有効成分とする注射用製剤 |
| CN113101374B (zh) * | 2021-04-08 | 2022-10-25 | 陕西科技大学 | 一种阿拉伯胶-明胶修饰牡丹籽油纳米脂质体及其制备方法 |
| TW202313032A (zh) | 2021-05-24 | 2023-04-01 | 日商富士軟片股份有限公司 | 處置劑 |
| CN117440810A (zh) | 2021-05-24 | 2024-01-23 | 富士胶片株式会社 | 抗肿瘤剂 |
| TW202345828A (zh) | 2022-03-31 | 2023-12-01 | 日商衛材R&D企管股份有限公司 | 脂質體組合物及包含脂質體之醫藥組合物 |
| TW202434243A (zh) | 2022-11-21 | 2024-09-01 | 日商富士軟片股份有限公司 | 含有內含拓普替康或其鹽之脂質體組成物及ｄｎａ損傷修復抑制劑之組合醫藥 |
| GB202315012D0 (en) * | 2023-09-29 | 2023-11-15 | Univ Bath | Composition |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL91664A (en) | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
| US5543152A (en) | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| DE69907243T2 (de) | 1998-09-16 | 2004-02-19 | Alza Corp., Mountain View | In liposomen eingeschlossene topoisomerase inhibitoren |
| WO2002002077A2 (en) | 2000-06-30 | 2002-01-10 | Inex Pharmaceuticals Corporation | Liposomal antineoplastic drugs and uses thereof |
| US20080075762A1 (en) | 2001-10-03 | 2008-03-27 | Paul Tardi | Compositions for delivery of drug combinations |
| US20070231379A1 (en) * | 2002-08-29 | 2007-10-04 | Slater James L | Liposome-entrapped topoisomerase inhibitors |
| DE602005018043D1 (de) | 2004-05-17 | 2010-01-14 | Tekmira Pharmaceuticals Corp | Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung |
| JP4990786B2 (ja) | 2004-11-05 | 2012-08-01 | イネックス ファーマシューティカルズ コーポレイション | 薬物リポソーム製剤を安定化するための組成物および方法 |
| ES2720160T3 (es) | 2005-05-09 | 2019-07-18 | Ono Pharmaceutical Co | Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas |
| WO2006127962A2 (en) * | 2005-05-25 | 2006-11-30 | Becton, Dickinson And Comapny | Particulate formulations for intradermal delivery of biologically active agents |
| US20080206139A1 (en) * | 2006-11-03 | 2008-08-28 | The Penn State Research Foundation | Delivery system for diagnostic and therapeutic agents |
| CN101485629B (zh) * | 2008-01-16 | 2013-01-23 | 沈阳药科大学 | 一种给药系统及其制备方法 |
| WO2009149150A2 (en) | 2008-06-03 | 2009-12-10 | Alza Corporation | Composition comprising liposome-entrapped doxorubicin and methods of administration |
| AR076634A1 (es) * | 2008-11-21 | 2011-06-29 | Medgenesis Therapeutix Inc | Composiciones y metodo para tratar desordenes del sistema nervioso central |
| US20100249073A1 (en) | 2009-03-27 | 2010-09-30 | Robert Sabin | Prophylactic and therapeutic treatment of Alzheimer's disease using phytic acid and phytate to reduce amyloid beta plaque and tau protein |
| SI2415470T1 (sl) * | 2009-03-30 | 2016-12-30 | Eisai R&D Management Co., Ltd. | Liposomski sestavek |
| US11357728B2 (en) * | 2009-10-26 | 2022-06-14 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Liposome having inner water phase containing sulfobutyl ether cyclodextrin salt |
| EP2531175A2 (en) * | 2010-02-01 | 2012-12-12 | Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. | Liposomes comprising amphipathic drugs and method for their preparation |
| CN103153285B (zh) | 2010-12-27 | 2016-10-12 | 泰尔茂株式会社 | 脂质体组合物及其制造方法 |
| EP3069785A1 (en) * | 2011-10-25 | 2016-09-21 | The University Of British Columbia | Limit size lipid nanoparticles and related methods |
| CN102764234A (zh) | 2012-08-03 | 2012-11-07 | 上海现代药物制剂工程研究中心有限公司 | 一种盐酸拓扑替康靶向脂质体制剂及其制备方法 |
| AU2013331077A1 (en) * | 2012-10-19 | 2015-04-16 | The Regents Of The University Of California | Treating tumors of the central nervous system |
| AU2014315287A1 (en) * | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| CN104771361B (zh) * | 2014-01-14 | 2018-06-01 | 中国科学院上海药物研究所 | 一种盐酸拓扑替康脂质体纳米制剂及其制备方法 |
| CA2943365A1 (en) | 2014-04-01 | 2015-10-08 | Childrens Hospital Los Angeles | Targeted polymerized nanoparticles for cancer treatment |
| JP6316182B2 (ja) | 2014-12-19 | 2018-04-25 | 富士フイルム株式会社 | リポソームの製造方法及びリポソーム製造装置 |
| MA43183A (fr) | 2015-11-02 | 2018-09-12 | Fujifilm Corp | Agent thérapeutique antitumoral contenant une composition liposomale à base de gemcitabine et kit associé |
| WO2017079303A1 (en) | 2015-11-02 | 2017-05-11 | The Cleveland Clinic Foundation | Sequentially orchestrated immune checkpoint therapy for the treatment and prevention of cancer |
| EP3535026A1 (en) | 2016-11-02 | 2019-09-11 | Ipsen Biopharm Limited | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
| MX2019006523A (es) | 2016-12-05 | 2019-10-15 | G1 Therapeutics Inc | Conservacion de respuesta inmunitaria durante regimenes de quimioterapia. |
| SMT202500440T1 (it) * | 2017-03-31 | 2026-01-12 | Fujifilm Corp | Composizione liposomiale e composizione farmaceutica |
| WO2019244979A1 (ja) | 2018-06-20 | 2019-12-26 | 富士フイルム株式会社 | 薬物を内包するリポソーム組成物および免疫チェックポイント阻害剤を含む組合せ医薬 |
| TWI837189B (zh) | 2018-10-01 | 2024-04-01 | 日商富士軟片股份有限公司 | 包含內含藥物之脂質體組成物及鉑製劑之組合醫藥 |
-
2018
- 2018-03-30 SM SM20250440T patent/SMT202500440T1/it unknown
- 2018-03-30 PT PT187769575T patent/PT3603620T/pt unknown
- 2018-03-30 ES ES18776957T patent/ES3055110T3/es active Active
- 2018-03-30 KR KR1020197028183A patent/KR102328463B1/ko active Active
- 2018-03-30 CN CN202111595172.4A patent/CN114224840A/zh active Pending
- 2018-03-30 EP EP18776957.5A patent/EP3603620B1/en active Active
- 2018-03-30 AU AU2018246024A patent/AU2018246024B2/en active Active
- 2018-03-30 SI SI201831273T patent/SI3603620T1/sl unknown
- 2018-03-30 LT LTEPPCT/JP2018/013783T patent/LT3603620T/lt unknown
- 2018-03-30 DK DK18776957.5T patent/DK3603620T3/da active
- 2018-03-30 CN CN202310994903.5A patent/CN116763733A/zh active Pending
- 2018-03-30 CA CA3058127A patent/CA3058127C/en active Active
- 2018-03-30 RU RU2019130500A patent/RU2734900C1/ru active
- 2018-03-30 CN CN201880023073.9A patent/CN110505869A/zh active Pending
- 2018-03-30 BR BR112019020406-7A patent/BR112019020406B1/pt active IP Right Grant
- 2018-03-30 CN CN202310994904.XA patent/CN116763734A/zh active Pending
- 2018-03-30 FI FIEP18776957.5T patent/FI3603620T3/fi active
- 2018-03-30 HR HRP20251519TT patent/HRP20251519T1/hr unknown
- 2018-03-30 JP JP2019509395A patent/JP6728482B2/ja active Active
- 2018-03-30 RS RS20251226A patent/RS67470B1/sr unknown
- 2018-03-30 PL PL18776957.5T patent/PL3603620T3/pl unknown
- 2018-03-30 WO PCT/JP2018/013783 patent/WO2018181963A1/ja not_active Ceased
-
2019
- 2019-09-26 US US16/583,518 patent/US11413244B2/en active Active
-
2020
- 2020-07-01 JP JP2020113828A patent/JP7012124B2/ja active Active
- 2020-10-26 US US17/079,759 patent/US11446247B2/en active Active
-
2022
- 2022-01-17 JP JP2022005193A patent/JP7278436B2/ja active Active
- 2022-08-05 US US17/882,144 patent/US20220370352A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL293377A (en) | Hsd17b13 variants and uses thereof | |
| PL3603620T3 (pl) | Kompozycja liposomowa i kompozycja farmaceutyczna | |
| IL289276A (en) | Treprostinil derivatives and compositions and uses thereof | |
| EP3513809A4 (en) | MEDICAL COMPOSITION | |
| ZA201802125B (en) | Pharmaceutical composition and application thereof | |
| PL3265448T3 (pl) | Proleki riluzolu i ich zastosowanie | |
| DK3655038T3 (da) | Farmaceutisk sammensætning | |
| PL3319612T3 (pl) | Oksysterole i sposoby ich stosowania | |
| DK3128005T3 (da) | Sirp-alfa-variantkonstruktioner og anvendelser deraf | |
| DK3412660T3 (da) | Sulfonamidderivat og farmaceutisk sammensætning indeholdende samme | |
| DK3634377T3 (da) | Farmaceutisk formulering | |
| EP3603642A4 (en) | PHARMACEUTICAL PREPARATION | |
| IL271073A (en) | B4galt1 variants and uses thereof | |
| DK3388085T3 (da) | Farmaceutisk sammensætning og anvendelser deraf | |
| DK3583943T3 (da) | Farmaceutisk sammensætning | |
| MA49905A (fr) | Polyesteramines et polyesterquats | |
| IL282157A (en) | Compounds and therapeutic uses thereof | |
| EP3646866A4 (en) | PHARMACEUTICAL PREPARATION | |
| IL269305A (en) | Cannabinoid formulations and dosage | |
| EP3417845A4 (en) | ALPHA FORMULATION COMPOSITION AND ALPHA YELLOW COMPOSITION | |
| SMT202400478T1 (it) | Composizione farmaceutica | |
| DK3302483T3 (da) | Farmaceutiske sammensætninger og anvendelse deraf | |
| DK3601277T3 (da) | Farmaceutisk formulering | |
| EP3305309A4 (en) | ANTICARIOGENIC AGENT AND ANTICARIAC COMPOSITION | |
| IT201700039351A1 (it) | Miscela antimeristematica e antigermogliante |